Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

NCT ID: NCT07025824

Last Updated: 2025-09-03

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 220 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-30
• Study Completion Date: 2028-12-31

Brief Summary

The aim of this study is to compare the effectiveness and tolerability of two conditioning chemotherapies prior to allogeneic stem cell transplantation.

The following will also be investigated:

• Survival
• Remission and Relapse rate
• Engraftment or graft failure
• Graft versus Host Disease (GvHD)

Conditions

AML - Acute Myeloid Leukemia; MDS (Myelodysplastic Syndrome)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treo - Arm

Treo d-4 - d-2 + Flud d-6 till d-2

Group Type: EXPERIMENTAL

Treosulfan (Treo)

Intervention Type: DRUG

10 g/m2 intravenous

Fludarabine (Flud)

Intervention Type: DRUG

30 mg/m2 intravenous

MEL - Arm

Mel d-2 + Flud d-6 till d-2

Group Type: ACTIVE_COMPARATOR

Melphalan (Mel)

Intervention Type: DRUG

140 mg/m2 intravenous

Fludarabine (Flud)

Intervention Type: DRUG

30 mg/m2 intravenous

Interventions

Treosulfan (Treo)

10 g/m2 intravenous

Intervention Type: DRUG

Melphalan (Mel)

140 mg/m2 intravenous

Intervention Type: DRUG

Fludarabine (Flud)

30 mg/m2 intravenous

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Informed consent signed by the patient capable of giving

2. Patient scheduled for allogeneic transplantation within the next 3 weeks

3. Age ≥ 18 years

4. AML or MDS according to WHO with indication for allogeneic HCT:

1. AML in first or second complete remission (CR) or complete remission with incomplete hematologic recovery (CRi/CRh) or morphologic leukemia-free state (MLFS)

2. MDS according to WHO

5. Increased risk for treatment-related toxicity by myeloablative conditioning according to at least one of the following criteria:

1. Patients aged ≥ 50 years at transplant and/or

2. HCT-CI > 2 and/or

3. AML or MDS scheduled for 2nd allogeneic HCT from different donor with minimum of 12 months after 1st allogeneic HCT

6. Availability of a suitable donor:

1. Matched sibling donor (MSD) or

2. matched unrelated donor (MUD, 10/10 HLA) or

3. mismatched unrelated donor (MMUD, single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent -DQB1 mismatch (9/10) shown by confirmatory typing) or

4. haploidentical family donor

7. Planned GvHD prophylaxis with standard PTCy (with 50mg/kg body weight on days +3 and +4)

8. No history of cardiac disease that preclude allogeneic HCT and absence of active symptoms, otherwise, documented left ventricular ejection fraction

• 40 %.

9. No need for supplementary oxygen on day of randomization

Exclusion Criteria

1. Patients with acute promyelocytic leukemia with t(15;17)(q22;q12)

2. Patients with graft failure after previous allogeneic HCT

3. Patients with scheduled 2nd allogeneic HCT within 12 months after 1st allogeneic HCT

4. Pretreatment with either melphalan or treosulfan within the last 12 months prior to randomization

5. Planned TBI as part of conditioning

6. Severe organ dysfunction defined by either one of the following criteria:

1. Serum bilirubin > 1.5 × ULN (if not considered Gilbert-syndrome) or

2. ALAT or ASAT > 5 × ULN

7. Uncontrolled infection at the time of randomization.

8. Active viral hepatitis unless serology demonstrates clearance of infection. Occult or prior hepatitis B virus (HBV) infection, defined as negative hepatitis B surface antigen and positive total hepatitis core antibodies, may be included if HBV DNA is undetectable, provided that patients are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody after vaccination or prior cured hepatitis B are eligible. Patients for hepatitis C virus (HCV) antibody are eligible provided PCR if negative for HCV RNA.

9. Pregnant or breastfeeding women

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

medac GmbH

INDUSTRY

Sponsor Role: collaborator

Technische Universität Dresden

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I

Dresden, , Germany

Universitätsmedizin Halle (Saale)

Halle, , Germany

Universitätsklinikum Schleswig-Holstein, Campus Kiel

Kiel, , Germany

Universitätsklinikum Münster, Medizinische Klinik A, KMT-Zentrum

Münster, , Germany

Countries

Germany

Central Contacts

Prof. Friedrich Stölzel, MD

Role: CONTACT

etal-5@ukdd.de

+49 431 500-22701

Desiree Kunadt, MD

Role: CONTACT

etal-5@ukdd.de

+49 351 458 19523

Other Identifiers

TUD-ETAL-5-084

Identifier Type: -

Identifier Source: org_study_id